Free Trial

Danaher (DHR) Stock Price, News & Analysis

+3.36 (+1.29%)
(As of 06/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
3.20 million shs
Average Volume
2.75 million shs
Market Capitalization
$195.99 billion
P/E Ratio
Dividend Yield
Price Target

Danaher MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
1.8% Upside
$269.29 Price Target
Short Interest
1.05% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
1.05mentions of Danaher in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$37.54 M Sold Last Quarter
Proj. Earnings Growth
From $7.63 to $8.71 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.25 out of 5 stars

Multi-Sector Conglomerates Sector

2nd out of 19 stocks

Process Control Instruments Industry

5th out of 13 stocks

DHR stock logo

About Danaher Stock (NYSE:DHR)

Danaher Corporation, founded in 1984 by brothers Stephen and Mitchell Rales, is a globally diversified conglomerate headquartered in Washington, D.C. The company has evolved into a major player across various industries, offering a wide range of products and services in the medical, industrial, and commercial sectors. Danaher's mission is to innovate and provide high-quality solutions that positively impact people's lives worldwide. Danaher's began in 1984 as a Massachusetts real estate investment trust called DMG, Inc. The company underwent several reorganizations and strategic acquisitions, culminating in its present-day structure and diverse product portfolio.

Danaher is involved in designing, manufacturing, and marketing a broad array of products and services. Its offerings span medical diagnostics equipment, life sciences and diagnostics tools, environmental solutions, water quality analysis systems, industrial automation tools, and other specialized instruments. Danaher's mission is to leverage its technological expertise and commitment to continuous improvement to develop innovative solutions that enhance human well-being and drive sustainable growth.

The company's diverse product portfolio includes cutting-edge medical diagnostic devices, scientific instruments used in research and healthcare settings, water quality monitoring systems, and automation equipment for industrial applications. Danaher caters to various markets, including healthcare, life sciences, diagnostics, environmental monitoring, and industrial automation. Its products and services find applications in research institutions, healthcare facilities, industrial manufacturers, and government organizations.

Danaher Corporation boasts a leadership team comprising highly accomplished individuals with diverse expertise, driving the company's success and strategic direction. At the helm is Steven M. Rales, the Co-Founder and Chairman, who played a pivotal role in establishing Danaher and has been instrumental in shaping its strategic vision. With his visionary approach, Rales has steered the company towards sustained growth and innovation. Rainer M. Blair holds the positions of President, Chief Executive Officer, and Director, leading Danaher's day-to-day operations and spearheading its growth strategies. Blair's dynamic leadership has been crucial in driving the company's expansion and ensuring its position as a market leader.

Danaher has displayed excellent financial performance in recent years, with consistent revenue growth and profitability. The company's financial stability and strategic acquisitions have contributed to its robust performance. Danaher's strong financials indicate its ability to generate revenue and profits, which has positively influenced investor sentiment and contributed to its favorable valuation.

Danaher's valuation metrics demonstrate positive investor sentiment and confidence in the company's future growth prospects. Its favorable price-to-earnings ratio and price-to-cash flow ratio reflect investor willingness to pay a premium for its earnings potential and cash generation capacity. Danaher's stock performance has been noteworthy, driven by its strong financials, strategic initiatives, and positive market sentiment.

Investors should closely monitor any recent news or events that may have impacted Danaher's share price, such as industry developments or major acquisitions. Danaher operates in diverse industries with various competitors. Its competitive advantages, including a broad product portfolio and emphasis on innovation, position it well within its industries.

Danaher has ample growth opportunities, including expansion into emerging markets, strategic acquisitions, and research and development investments. The company's strong focus on continuous improvement and customer-centric solutions will drive its pursuit of growth opportunities.

Danaher faces potential risks and challenges, including market fluctuations, regulatory changes, and economic uncertainties. However, its proactive risk management strategies mitigate potential impacts on the company's financial performance.

DHR Stock Price History

DHR Stock News Headlines

Danaher (NYSE:DHR) Now Covered by Jefferies Financial Group
Danaher Corporation (DHR)
Danaher Announces Quarterly Dividend
DHR May 2024 257.500 call
Danaher Corporation: A Good Medium Term Bet
Danaher Q1: The Worst Time Has Already Passed
See More Headlines
Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 4/26 Dividend
Last Earnings
Dividend Payable
Ex-Dividend for 7/26 Dividend
Next Earnings (Estimated)
Dividend Payable
Fiscal Year End

Industry, Sector and Symbol

Process control instruments
Industrial Conglomerates
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
$4.76 billion
Pretax Margin


Sales & Book Value

Annual Sales
$23.74 billion
Cash Flow
$10.59 per share
Book Value
$72.39 per share


Free Float
Market Cap
$195.99 billion

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Should I Buy Danaher Stock? DHR Pros and Cons Explained


Here are some ways that investors could benefit from investing in Danaher Co.:

  • Danaher Co. has shown consistent revenue growth over the past few quarters, indicating a strong financial performance.
  • The company's acquisition strategy has been successful, expanding its product portfolio and market reach.
  • Recent product innovations, such as the launch of their latest diagnostic equipment, have received positive reviews in the industry.
  • Danaher Co.'s stock price has been steadily increasing, reflecting investor confidence in the company's future prospects.
  • The company's strong presence in the life sciences and healthcare sectors provides stability and growth opportunities.


Investors should be bearish about investing in Danaher Co. for these reasons:

  • Market competition in the life sciences industry is intense, leading to potential pricing pressures and margin challenges for Danaher Co.
  • Global economic uncertainties may impact the demand for Danaher Co.'s products and services, affecting revenue growth.
  • Regulatory changes in the healthcare sector could pose risks to Danaher Co.'s operations and profitability.
  • Fluctuations in raw material prices could impact the company's manufacturing costs and overall profitability.
  • Investors should closely monitor any potential impact of geopolitical events on Danaher Co.'s international operations and supply chain.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 4, 2024. Please send any questions or comments about these Danaher pros and cons to

DHR Stock Analysis - Frequently Asked Questions

Should I buy or sell Danaher stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last twelve months. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DHR shares.
View DHR analyst ratings
or view top-rated stocks.

What is Danaher's stock price target for 2024?

15 analysts have issued 12-month price targets for Danaher's stock. Their DHR share price targets range from $205.00 to $295.00. On average, they expect the company's share price to reach $269.29 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price.
View analysts price targets for DHR
or view top-rated stocks among Wall Street analysts.

How have DHR shares performed in 2024?

Danaher's stock was trading at $231.34 at the beginning of 2024. Since then, DHR shares have increased by 14.4% and is now trading at $264.61.
View the best growth stocks for 2024 here

Are investors shorting Danaher?

Danaher saw a increase in short interest in May. As of May 31st, there was short interest totaling 7,120,000 shares, an increase of 18.5% from the May 15th total of 6,010,000 shares. Based on an average trading volume of 2,720,000 shares, the short-interest ratio is currently 2.6 days. Approximately 1.1% of the company's stock are sold short.
View Danaher's Short Interest

When is Danaher's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 23rd 2024.
View our DHR earnings forecast

How were Danaher's earnings last quarter?

Danaher Co. (NYSE:DHR) released its quarterly earnings data on Tuesday, April, 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts' consensus estimates of $1.72 by $0.20. The conglomerate had revenue of $5.80 billion for the quarter, compared to analysts' expectations of $5.62 billion. Danaher had a trailing twelve-month return on equity of 11.43% and a net margin of 16.78%. Danaher's quarterly revenue was down 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.36 EPS.
Read the conference call transcript

How often does Danaher pay dividends? What is the dividend yield for Danaher?

Danaher announced a quarterly dividend on Tuesday, May 7th. Investors of record on Friday, June 28th will be paid a dividend of $0.27 per share on Friday, July 26th. This represents a $1.08 annualized dividend and a yield of 0.41%. The ex-dividend date is Friday, June 28th.
Read our dividend analysis for DHR

Is Danaher a good dividend stock?

Danaher (NYSE:DHR) pays an annual dividend of $1.08 per share and currently has a dividend yield of 0.40%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 18.31%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DHR will have a dividend payout ratio of 12.40% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DHR.

What is Rainer M. Blair's approval rating as Danaher's CEO?

27 employees have rated Danaher Chief Executive Officer Rainer M. Blair on Rainer M. Blair has an approval rating of 98% among the company's employees. This puts Rainer M. Blair in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Danaher own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Danaher investors own include NVIDIA (NVDA), Home Depot (HD), Walt Disney (DIS), Johnson & Johnson (JNJ), Adobe (ADBE), Intel (INTC), Alibaba Group (BABA), Mastercard (MA), PayPal (PYPL) and AbbVie (ABBV).

Who are Danaher's major shareholders?

Danaher's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.12%), Price T Rowe Associates Inc. MD (2.18%), Capital International Investors (2.04%), Bank of New York Mellon Corp (1.18%), Capital Research Global Investors (0.69%) and Capital World Investors (0.67%). Insiders that own company stock include Alan G Spoon, Angela S Lalor, Angela S Lalor, Brian W Ellis, Daniel Raskas, Elias A Zerhouni, Georgeann Couchara, Jennifer Honeycutt, Joakim Weidemanis, Jose-Carlos Gutierrez-Ramos, Linda Filler, Linda P Hefner, Matthew Mcgrew, Mitchell P Rales, Rainer Blair, Raymond C Stevens, Robert S Lutz, Teri List and Walter G Lohr.
View institutional ownership trends

How do I buy shares of Danaher?

Shares of DHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Danaher have any subsidiaries?
The following companies are subsidiares of Danaher: AB SCIEX, AB Sciex LLC, AB Sciex LP, AB Sciex Pte Ltd., Accu-Sort Systems, Acme Cleveland Corporation, Advanced Vision Technology, Aldevron, Aldevron L.L.C., American Precision Industries, Applied Biosystems, Applitek NV, Aquatic Infomatics ULC, Aquatic Informatics, Armstrong Tools, BC Distribution BV, Beckman Coulter, Beckman Coulter Australia Pty Ltd, Beckman Coulter Biotechnology Suzhou Co. Ltd., Beckman Coulter Canada LP, Beckman Coulter Commercial Enterprise China Co. Ltd., Beckman Coulter France S.A.S., Beckman Coulter G.m.b.H., Beckman Coulter Genomics Inc., Beckman Coulter Hong Kong Limited, Beckman Coulter Inc., Beckman Coulter India Private Limited, Beckman Coulter International SA, Beckman Coulter International Shanghai Trading Co., Beckman Coulter Ireland Inc., Beckman Coulter K.K., Beckman Coulter Korea Ltd, Beckman Coulter Laboratory Systems Suzhou Co. Ltd., Beckman Coulter Limited Liability Company, Beckman Coulter Nederland B.V., Beckman Coulter Nippon GK, Beckman Coulter S.L.U., Beckman Coulter Saudi Arabia Co.Ltd., Beckman Coulter Srl, Beckman Coulter Taiwan Inc., Beckman Coulter United Kingdom Limited, Beckman Coulter de Mexico S.A. de C.V., Beckman Finance ApS, Biacore International AB, Biosafe S.A., Blue Software LLC, Cepheid, Cepheid AB, Cepheid Canada ULC, Cepheid Europe SAS, Cepheid GmbH, Cepheid HBDC SAS, Cepheid India Private Limited, Cepheid UK Ltd., ChemTreat, ChemTreat Inc., Cispus Hong Kong Holding Limited, Cytiva, Cytiva BioProcess R&D AB, Cytiva Biotechnology Guangzhou Co. Ltd., Cytiva Biotechnology Hang Zhou Co. Ltd., Cytiva Europe GmbH, Cytiva Sweden AB, DCHL Holding BV, DH Denmark Holding ApS, DH Europe Finance II Sarl, DH Europe Finance Sarl, DH Holding Italia SRL, DH Holdings Germany LLC, DH II Luxembourg Sarl, DH Japan Finance Sarl, DH Switzerland Finance Sarl, DH Technologies Development Pte Ltd., DHCY Limited, DHKAB Company AB, DTIL Ireland Holdings Ltd., Danaher China Holdings Ltd., Danaher Finance Company AB, Danaher HK Holdings Ltd., Danaher Medical ApS, Danaher Shanghai Management Co. Ltd., Delta Consolidated Industries, Devicore Medical Products Inc., Easco Hand Tools, Esko, Esko BV, Esko Graphics BV, Esko Graphics Inc., Esko Software BV, Fluke, GE Biopharma, Gelman Sciences Inc., Gendex, Genetix Group, Gilbarco Veeder Root, Gilzoni Ltd., Global Life Sciences Solutions Austria GmbH & Co. KG, Global Life Sciences Solutions Germany GmbH, Global Life Sciences Solutions Korea Ltd., Global Life Sciences Solutions Manufacturing UK Ltd, Global Life Sciences Solutions Operations UK Ltd, Global Life Sciences Solutions Singapore Pte Ltd, Global Life Sciences Solutions USA LLC, Global Life Sciences Technologies Japan KK, Global Life Sciences Technologies Shanghai Co Ltd., Hach Company, Hach Lange GmbH, Hach Lange Sàrl, Hach Water Quality Analytical Instru. Shanghai Co. Ltd., HemoCue AB, HyClone Laboratories LLC, Hybritech Incorporated, Hyclone Life Sciences Solutions India Private Limited, ID Business Solutions Limited, IDBS Group, IRIS International, Imaging Sciences International, Immunotech Sro, Intabio LLC, Integrated DNA Technologies, Integrated DNA Technologies BVBA, Integrated DNA Technologies Inc., Integrated DNA Technologies Pte. Ltd., Intermountain Life Sciences LLC, Iris International Inc., KaVo, KaVo Kerr, Kaltenbach & Voigt, Keithley Instruments, Kipp & Zonen BV, Kollmorgen, Labcyte Inc., Laetus, Launchchange Holding Company, Leica Biosystems Imaging Inc., Leica Biosystems Melbourne Pty Ltd, Leica Biosystems Newcastle Limited, Leica Biosystems Nussloch GmbH, Leica Biosystems Richmond Inc., Leica Instruments Singapore Pte Limited, Leica Microsystems, Leica Microsystems CMS GmbH, Leica Microsystems Cambridge Limited, Leica Microsystems IR GmbH, Leica Microsystems Inc., Leica Microsystems Limited, Leica Microsystems UK Limited, Leica Mikrosysteme GmbH, Leica Mikrosysteme Vertrieb GmbH, Life Sciences Holdings France SAS, Life Sciences IP Holdings Corporation, Lifschultz Industries, Linx Printing Technologies, Linx Printing Technologies Limited, MDS Analytical Technologies, Marconi Data Systems, Microtest, Molecular Devices, Molecular Devices LLC, Navman Wireless, Navman Wireless OEM Solutions, Nihon Pall Ltd., Nobel Biocare, OTT Hydromet Corp, Pall Aeropower Corporation, Pall Artelis BVBA, Pall Asia Holdings Inc., Pall Austar Lifesciences Limited, Pall Australia Pty. Ltd., Pall Austria Filter Ges.m.b.h, Pall Canada ULC, Pall China Co. Ltd., Pall Corporation, Pall Europe Limited, Pall Filtersystems GmbH, Pall Filtration Pte. Ltd., Pall Filtration and Separations Group Inc., Pall France SAS, Pall GmbH, Pall India Pvt. Ltd., Pall International Sarl, Pall Italia Srl, Pall Korea Ltd., Pall Life Sciences Belgium BV, Pall Life Sciences Puerto Rico LLC, Pall Manufacturing UK Limited, Pall Medistad BV, Pall Netherlands BV Irish Branch, Pall Schweiz GmbH, Pall Technology UK Limited, PaloDEX, Pantone LLC, Pelton & Crane, Phenomenex, Phenomenex Inc., Precision NanoSystems, Precision Nanosystems ULC, Radiometer, Radiometer Medical ApS, Radiometer Turku Oy, Raytek, Reytek Corporation, Sea-Bird Electronics Inc., Sedaru Inc., Shanghai AB Sciex Analytical Instrument Trading Co. Ltd., Skyland Analytics Inc., Sutron, Swift Biosciences Inc., Sybron Dental Specialties, Tektronix, Thomson Industries, Trojan Technologies, Trojan Technologies Group ULC, VSS Monitoring, Vanrx Pharmasystems Inc., Videojet Do Brasil Comércio de Equipamentos Para Codificação Industrial Ltda., Videojet Technologies Europe B.V., Videojet Technologies GmbH, Videojet Technologies Inc., Videojet Technologies S Pte.Ltd., Viridor Waste Management Limited, Vision Systems Limited, Willett International, X-Ray Optical Systems Inc., X-Rite, X-Rite Europe GmbH, X-Rite Incorporated, XOS, Yukon Hong Kong Holding Limited, and Zhuhai S.E.Z. Videojet Electronics Ltd..
Read More
This page (NYSE:DHR) was last updated on 6/13/2024 by Staff

From Our Partners